Plain-English translation of NCT07592689 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Major Depressive Disorder research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment called for people with major depression. The study will compare at two different doses against placebo (a pill with no active ingredient) to see if the medication can help reduce depression symptoms. Participants will be followed for up to one year to understand how well and safely this medication works.
Major depression is a serious condition that affects millions of people, and current treatments don't work for everyone or have unwanted side effects. This trial is exploring whether this medication, which works on a different pathway in the brain than many existing antidepressants, could offer a new option for people struggling with depression.
You likely qualify if…
You likely don't qualify if…
You would visit the research site several times over 12 weeks, during which you would take either the new medication or a placebo as a single dose. After that initial 12-week phase, you would continue in an extended phase for an additional 40 weeks where researchers would monitor your symptoms and consider whether retreatment might be helpful. Throughout the study, you would complete depression symptom assessments and be evaluated for safety.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States